CUPERTINO, Calif., Apr 8, 2002 (BUSINESS WIRE) — In conjunction with DURECT
Corporation’s (Nasdaq:DRRX) first quarter financial results press release, you
are invited to listen to its conference call that will be broadcast live over
the Internet on Wednesday, April 24, 2002 at 4:30 p.m. EDT with Jim Brown,
President and Chief Executive Officer, Tom Schreck, Chief Financial Officer,
Felix Theeuwes, Chairman and Chief Scientific Officer.
What: DURECT Corporation's First Quarter 2002 Earnings
Conference Call
When: Wednesday, April 24th, 2002, 4:30 p.m. EDT
Where: www.www.durect.com and click "Investor Relations"
How: Live over the Internet -- Simply log on to the Web at
the address listed above.
Contact: Suzanne Watson, DURECT Corporation, 408-864-7489,
suzanne.watson@durect.com
If you are unable to participate during the live webcast, the call will be
archived on DURECT’s website under Audio Archive in the “Investor Relations”
section.
DURECT Corporation (www.www.durect.com) is pioneering the development and
commercialization of pharmaceutical systems for the treatment of chronic
debilitating diseases and enabling biotechnology-based pharmaceutical products.
DURECT’s goal is to deliver the right drug to the right site in the right amount
at the right time. DURECT’s lead product in development, the CHRONOGESIC(TM)
(sufentanil) Pain Therapy System, a 3-month product for the treatment of chronic
pain, completed a pilot phase III study in December 2001. DURECT owns three
proprietary drug delivery platform technologies, including the SABER(TM)
Delivery System (a patented and versatile depot injectable useful for protein
delivery), the MICRODUR(TM) Biodegradable Microparticulates (microspheres
injectable system) and the DURIN(TM) Biodegradable Implant (drug-loaded implant
system).
CHRONOGESIC(TM)is a trademark of DURECT Corporation. SABER(TM), MICRODUR(TM)and
DURIN(TM)are trademarks of Southern BioSystems, Inc., a wholly owned subsidiary
of DURECT Corporation.
The statements in this press release regarding DURECT’s products in development,
expected product benefits, product development plans, future clinical trials or
potential product markets are forward-looking statements involving risks and
uncertainties that can cause actual results to differ materially from those in
such forward-looking statements. Potential risks and uncertainties include, but
are not limited to, DURECT’s ability to research, develop, manufacture and
commercialize its products, obtain product and manufacturing approvals from
regulatory agencies, manage its growth and expenses, finance its activities and
operations, as well as marketplace acceptance of DURECT’s products. Further
information regarding these and other risks is included in DURECT’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2001 filed with the
SEC on March 28, 2002, under the heading “Factors that may affect future
results,” and other periodic reports filed with the SEC. CHRONOGESIC is under
development by DURECT and has not been submitted or approved for
commercialization by the US Food and Drug Administration or other health
authorities.
CONTACT: DURECT Corporation
Schond L. Greenway, 408/777-1417
schond.greenway@durect.com
URL: http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2002 Business Wire. All rights reserved.